$ZOM
Zomedica Corp.

2023 Q2 Form 10-Q Financial Statement

#000155837023009389 Filed on May 11, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1
Revenue $6.020M $5.482M
YoY Change 2073.29% 46.15%
Cost Of Revenue $1.972M $1.647M
YoY Change 62.98% 66.36%
Gross Profit $4.048M $3.835M
YoY Change 33.33% 38.9%
Gross Profit Margin 67.24% 69.96%
Selling, General & Admin $9.931M $10.43M
YoY Change 15.52% 55.1%
% of Gross Profit 245.33% 271.94%
Research & Development $859.0K $918.0K
YoY Change 169.28% 161.54%
% of Gross Profit 21.22% 23.94%
Depreciation & Amortization $340.0K $164.0K
YoY Change 378.87% 100.0%
% of Gross Profit 8.4% 4.28%
Operating Expenses $10.79M $11.35M
YoY Change 21.02% 60.38%
Operating Profit -$6.742M -$7.512M
YoY Change 14.66% 74.13%
Interest Expense $62.00K $50.00K
YoY Change -72.44% -50.0%
% of Operating Profit
Other Income/Expense, Net -$1.000K
YoY Change -200.0%
Pretax Income -$5.326M -$6.177M
YoY Change -5.82% 46.55%
Income Tax -$77.00K $208.0K
% Of Pretax Income
Net Earnings -$5.249M -$6.385M
YoY Change -0.46% 62.18%
Net Earnings / Revenue -87.19% -116.47%
Basic Earnings Per Share -$0.01 -$0.01
Diluted Earnings Per Share -$0.01 -$0.01
COMMON SHARES
Basic Shares Outstanding 979.9M 979.9M
Diluted Shares Outstanding 979.9M 979.9M

Balance Sheet

Concept 2023 Q2 2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $130.5M $121.1M
YoY Change -30.14% -37.06%
Cash & Equivalents $27.95M $8.353M
Short-Term Investments $102.5M $112.7M
Other Short-Term Assets $3.562M $4.856M
YoY Change 53.87% 186.32%
Inventory $3.634M $2.743M
Prepaid Expenses
Receivables $654.0K $428.0K
Other Receivables $1.302M $1.085M
Total Short-Term Assets $139.6M $130.2M
YoY Change -28.26% -34.41%
LONG-TERM ASSETS
Property, Plant & Equipment $7.291M $6.799M
YoY Change 326.37% 395.19%
Goodwill $63.98M $63.98M
YoY Change 47.8% 47.8%
Intangibles $48.07M $48.43M
YoY Change 49.77% 49.3%
Long-Term Investments $11.92M $26.41M
YoY Change 1092.0%
Other Assets $265.0K $265.0K
YoY Change 0.0% 0.0%
Total Long-Term Assets $135.2M $149.4M
YoY Change 67.16% 87.87%
TOTAL ASSETS
Total Short-Term Assets $139.6M $130.2M
Total Long-Term Assets $135.2M $149.4M
Total Assets $274.8M $279.6M
YoY Change -0.25% 0.58%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $6.144M $7.419M
YoY Change 76.0% 138.63%
Accrued Expenses $74.00K $233.0K
YoY Change 80.49% 7.37%
Deferred Revenue $255.0K $242.0K
YoY Change 66.67% 63.51%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $641.0K $641.0K
YoY Change 22.56% 51.9%
Total Short-Term Liabilities $7.210M $8.597M
YoY Change 61.15% 108.77%
LONG-TERM LIABILITIES
Long-Term Debt $781.0K $941.0K
YoY Change -34.04% 10.06%
Other Long-Term Liabilities $2.181M $1.965M
YoY Change 457.8% 402.56%
Total Long-Term Liabilities $2.181M $1.965M
YoY Change 457.8% 402.56%
TOTAL LIABILITIES
Total Short-Term Liabilities $7.210M $8.597M
Total Long-Term Liabilities $2.181M $1.965M
Total Liabilities $15.30M $16.54M
YoY Change 65.25% 84.83%
SHAREHOLDERS EQUITY
Retained Earnings -$148.0M -$142.8M
YoY Change 15.11% 15.78%
Common Stock $408.1M $406.4M
YoY Change 3.37% 3.59%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $259.5M $263.1M
YoY Change
Total Liabilities & Shareholders Equity $274.8M $279.6M
YoY Change -0.25% 0.58%

Cashflow Statement

Concept 2023 Q2 2023 Q1
OPERATING ACTIVITIES
Net Income -$5.249M -$6.385M
YoY Change -0.46% 62.18%
Depreciation, Depletion And Amortization $340.0K $164.0K
YoY Change 378.87% 100.0%
Cash From Operating Activities -$3.676M -$4.257M
YoY Change -9.14% 72.28%
INVESTING ACTIVITIES
Capital Expenditures $96.00K $113.0K
YoY Change -241.18% 36.14%
Acquisitions
YoY Change
Other Investing Activities $23.42M -$10.68M
YoY Change -1810.52% 8582.11%
Cash From Investing Activities $23.32M -$14.79M
YoY Change -1722.89% 7080.58%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities
YoY Change
NET CHANGE
Cash From Operating Activities -3.676M -4.257M
Cash From Investing Activities 23.32M -14.79M
Cash From Financing Activities
Net Change In Cash 19.64M -19.05M
YoY Change -458.29% 611.58%
FREE CASH FLOW
Cash From Operating Activities -$3.676M -$4.257M
Capital Expenditures $96.00K $113.0K
Free Cash Flow -$3.772M -$4.370M
YoY Change -5.18% 71.1%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q4 us-gaap Inventory Net
InventoryNet
2746000
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4856000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3799000
CY2023Q1 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
1085000
CY2022Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
1268000
CY2022Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
27000
CY2023Q1 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-263000
CY2022Q1 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
25000
CY2023Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
721000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-118000
CY2023Q1 us-gaap Increase Decrease In Accrued Taxes Payable
IncreaseDecreaseInAccruedTaxesPayable
46000
CY2022Q1 us-gaap Increase Decrease In Accrued Taxes Payable
IncreaseDecreaseInAccruedTaxesPayable
-23000
CY2022Q1 us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
-279000
CY2023Q1 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
-16000
CY2022Q1 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
-40000
CY2023Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
116000
CY2023Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001684144
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
979949668
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
979949668
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
00-0000000
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
001-38298
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
Zomedica Corp.
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
Z4
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
100 Phoenix Drive
CY2023Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 125
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Ann Arbor
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
MI
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
48108
CY2023Q1 dei City Area Code
CityAreaCode
734
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
369-2555
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q1 dei Security12b Title
Security12bTitle
Common Shares
CY2023Q1 dei Trading Symbol
TradingSymbol
ZOM
CY2023Q1 dei Security Exchange Name
SecurityExchangeName
NYSE
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
979949668
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8353000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
27399000
CY2023Q1 us-gaap Debt Securities Available For Sale Excluding Accrued Interest Current
DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
112698000
CY2022Q4 us-gaap Debt Securities Available For Sale Excluding Accrued Interest Current
DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
87693000
CY2023Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
428000
CY2023Q1 us-gaap Assets Current
AssetsCurrent
130163000
CY2022Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-35000
CY2023Q1 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
134000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
123501000
CY2023Q1 us-gaap Prepaid Expense And Other Assets Noncurrent
PrepaidExpenseAndOtherAssetsNoncurrent
153000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Noncurrent
PrepaidExpenseAndOtherAssetsNoncurrent
188000
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6799000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6809000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
596000
CY2023Q1 us-gaap Inventory Net
InventoryNet
2743000
CY2023Q1 zom Asset Construction In Progress Non Current
AssetConstructionInProgressNonCurrent
1886000
CY2022Q4 zom Asset Construction In Progress Non Current
AssetConstructionInProgressNonCurrent
692000
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1511000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1665000
CY2023Q1 us-gaap Goodwill
Goodwill
63979000
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
5482000
CY2022Q4 us-gaap Goodwill
Goodwill
63979000
CY2023Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
48433000
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
41799000
CY2023Q1 us-gaap Debt Securities Available For Sale Excluding Accrued Interest Noncurrent
DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent
26409000
CY2022Q4 us-gaap Debt Securities Available For Sale Excluding Accrued Interest Noncurrent
DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent
40712000
CY2023Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
265000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
265000
CY2023Q1 us-gaap Assets
Assets
279598000
CY2022Q4 us-gaap Assets
Assets
279610000
CY2023Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
7419000
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
6698000
CY2023Q1 us-gaap Accrued Income Taxes
AccruedIncomeTaxes
233000
CY2022Q4 us-gaap Accrued Income Taxes
AccruedIncomeTaxes
187000
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
641000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
641000
CY2023Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
242000
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
207000
CY2023Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
62000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
78000
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
8597000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
7811000
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
941000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1097000
CY2023Q1 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
1245000
CY2022Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
1245000
CY2023Q1 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
263000
CY2022Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
182000
CY2023Q1 zom Supplier Finance Program Obligation Noncurrent
SupplierFinanceProgramObligationNoncurrent
3529000
CY2023Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1965000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1883000
CY2023Q1 us-gaap Liabilities
Liabilities
16540000
CY2022Q4 us-gaap Liabilities
Liabilities
12218000
CY2023Q1 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2022Q4 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
979949668
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
979949668
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
380973000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
380973000
CY2023Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
25431000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
23666000
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-142789000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-136404000
CY2023Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-557000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-843000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
263058000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
267392000
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
279598000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
279610000
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3751000
CY2023Q1 us-gaap Cost Of Revenue
CostOfRevenue
1647000
CY2022Q1 us-gaap Cost Of Revenue
CostOfRevenue
1011000
CY2023Q1 us-gaap Gross Profit
GrossProfit
3835000
CY2022Q1 us-gaap Gross Profit
GrossProfit
2740000
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
918000
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
351000
CY2023Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
10429000
CY2022Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
6703000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-7512000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-4314000
CY2023Q1 us-gaap Investment Income Net
InvestmentIncomeNet
1412000
CY2022Q1 us-gaap Investment Income Net
InvestmentIncomeNet
107000
CY2023Q1 us-gaap Interest Expense
InterestExpense
50000
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1000
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1000
CY2023Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-26000
CY2022Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-7000
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-6177000
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-4215000
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
208000
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-278000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-6385000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-3937000
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
283000
CY2023Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
3000
CY2022Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
51000
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-6099000
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3886000
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
979949668
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
979899668
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.007
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.004
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
267392000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1765000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-6385000
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
286000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
263058000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
270886000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2041000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-3937000
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
51000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
269041000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-6385000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-3937000
CY2023Q1 us-gaap Depreciation
Depreciation
164000
CY2022Q1 us-gaap Depreciation
Depreciation
82000
CY2023Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1199000
CY2022Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
737000
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1765000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
2041000
CY2023Q1 zom Non Cash Portion Of Rent Expense
NonCashPortionOfRentExpense
-1000
CY2023Q1 us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
654000
CY2023Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
731000
CY2022Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1005000
CY2023Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
1022000
CY2022Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-128000
CY2023Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-144000
CY2022Q1 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
30000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4257000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2471000
CY2023Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
8072000
CY2023Q1 us-gaap Payments To Acquire Notes Receivable
PaymentsToAcquireNotesReceivable
1750000
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
113000
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
83000
CY2023Q1 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
4000000
CY2023Q1 us-gaap Payments To Acquire Other Productive Assets
PaymentsToAcquireOtherProductiveAssets
857000
CY2022Q1 us-gaap Payments To Acquire Other Productive Assets
PaymentsToAcquireOtherProductiveAssets
123000
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-14792000
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-206000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-19049000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-2677000
CY2023Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
3000
CY2022Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
62000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
27399000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
194952000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8353000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
192337000
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
283000
CY2023Q1 us-gaap Construction In Progress Expenditures Incurred But Not Yet Paid
ConstructionInProgressExpendituresIncurredButNotYetPaid
401000
CY2023Q1 zom Transfer Of Inventory Into Property And Equipment
TransferOfInventoryIntoPropertyAndEquipment
738000
CY2022Q1 zom Transfer Of Inventory Into Property And Equipment
TransferOfInventoryIntoPropertyAndEquipment
246000
CY2023Q1 us-gaap Proceeds From Interest And Dividends Received
ProceedsFromInterestAndDividendsReceived
783000
CY2022Q1 us-gaap Proceeds From Interest And Dividends Received
ProceedsFromInterestAndDividendsReceived
90000
CY2022 zom Operating Lease Liability Additions
OperatingLeaseLiabilityAdditions
2520000
CY2023Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
1071000
CY2023Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Estimates and Assumptions</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In preparing these financial statements, management was required to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses. These estimates and assumptions are based on our historical experience, the terms of existing contracts, our evaluation of trends in the industry, information provided by our customers and suppliers and information available from other outside sources, as appropriate. These estimates and assumptions are subject to an inherent degree of uncertainty. We are not presently aware of any events or circumstances that would require us to update such estimates and assumptions or revise the carrying value of our assets or liabilities. Our estimates may change, however, as new events occur, and additional information is obtained. As a result, actual results may differ significantly from our estimates, and any such differences may be material to our financial statements.</p>
CY2023Q1 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Comparative Figures</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">A portion of depreciation expense has been stated as part of cost of revenue for $54. The consolidated statements of income and comprehensive income for the period ended March 31, 2022 have been adjusted for $21 of depreciation that was included in sales, general, and administrative expense. This amount has been reclassified to cost of revenue to conform to the current year presentation. The change in presentation had no effect on the reported results of operations and does not affect previously reported cash flows from operating activities in the consolidated statements of cash flows.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">To better align with the way in which we measure and track our business, we have changed the categorization of products within our segmentation of revenue. A portion of the products in our Therapeutics segment were previously designated as instruments and trodes in our form 10Q for the period ending March 31, 2022. These products have since been renamed to be capital and consumables to better align with our other platforms and to provide a more consistent baseline for comparison of the product lines within. Capital refers to the devices we sell within our PulseVet<sup style="font-size:6.75pt;line-height:100%;top:0pt;vertical-align:top;">®</sup>, Revo Squared<sup style="font-size:6.75pt;line-height:100%;top:0pt;vertical-align:top;">®</sup>, and VetGuardian<sup style="font-size:6.75pt;line-height:100%;top:0pt;vertical-align:top;">®</sup> product lines. Consumables continues to include our TRUFORMA<sup style="font-size:6.75pt;line-height:100%;top:0pt;vertical-align:top;">®</sup> cartridges as it did last year and now includes our PulseVet trodes as well as our Assisi<sup style="font-size:6.75pt;line-height:100%;top:0pt;vertical-align:top;">®</sup>  products. There have been no changes to the overall sales numbers for our Diagnostics and Therapeutics segments, only the product names making up the total.</p>
CY2023Q1 us-gaap Cost Of Goods And Services Sold Depreciation
CostOfGoodsAndServicesSoldDepreciation
54000
CY2023Q1 zom Accounts Receivables Payment Term
AccountsReceivablesPaymentTerm
P30D
CY2023Q1 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
47000
CY2022 us-gaap Operating Lease Payments
OperatingLeasePayments
896000
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
5482000
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3751000
CY2023Q1 us-gaap Investment Owned At Cost
InvestmentOwnedAtCost
143609000
CY2023Q1 zom Investment Securities Accumulated Accretion Or Amortization
InvestmentSecuritiesAccumulatedAccretionOrAmortization
1183000
CY2023Q1 us-gaap Debt Securities Available For Sale Accumulated Gross Unrealized Gain Loss Before Tax
DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax
778000
CY2023Q1 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
144014000
CY2023Q1 us-gaap Interest Receivable Current
InterestReceivableCurrent
690000
CY2023Q1 us-gaap Investment Owned At Cost
InvestmentOwnedAtCost
143609000
CY2023Q1 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
144014000
CY2023Q1 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
1734000
CY2022Q4 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
1685000
CY2023Q1 us-gaap Inventory Finished Goods And Work In Process
InventoryFinishedGoodsAndWorkInProcess
445000
CY2022Q4 us-gaap Inventory Finished Goods And Work In Process
InventoryFinishedGoodsAndWorkInProcess
182000
CY2023Q1 zom Inventory Purchase
InventoryPurchase
588000
CY2022Q4 zom Inventory Purchase
InventoryPurchase
919000
CY2023Q1 us-gaap Inventory Gross
InventoryGross
2767000
CY2022Q4 us-gaap Inventory Gross
InventoryGross
2786000
CY2023Q1 us-gaap Inventory Adjustments
InventoryAdjustments
24000
CY2022Q4 us-gaap Inventory Adjustments
InventoryAdjustments
40000
CY2023Q1 us-gaap Inventory Net
InventoryNet
2743000
CY2022Q4 us-gaap Inventory Net
InventoryNet
2746000
CY2023Q1 us-gaap Deposit Assets
DepositAssets
2274000
CY2022Q4 us-gaap Deposit Assets
DepositAssets
1886000
CY2023Q1 us-gaap Prepaid Advertising
PrepaidAdvertising
72000
CY2022Q4 us-gaap Prepaid Advertising
PrepaidAdvertising
114000
CY2023Q1 us-gaap Prepaid Insurance
PrepaidInsurance
570000
CY2022Q4 us-gaap Prepaid Insurance
PrepaidInsurance
614000
CY2023Q1 us-gaap Prepaid Taxes
PrepaidTaxes
1733000
CY2022Q4 us-gaap Prepaid Taxes
PrepaidTaxes
753000
CY2023Q1 us-gaap Other Assets Miscellaneous
OtherAssetsMiscellaneous
360000
CY2022Q4 us-gaap Other Assets Miscellaneous
OtherAssetsMiscellaneous
620000
CY2023Q1 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
5009000
CY2022Q4 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
3987000
CY2023Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
8240000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
8086000
CY2023Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1441000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1277000
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6799000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6809000
CY2023Q1 us-gaap Depreciation
Depreciation
164000
CY2022Q1 us-gaap Depreciation
Depreciation
82000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1665000
CY2023Q1 zom Operating Lease Liability Additions
OperatingLeaseLiabilityAdditions
2520000
CY2023Q1 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
54312000
CY2022Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
46479000
CY2023Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
5879000
CY2022Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
4680000
CY2023Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
48433000
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
41799000
CY2023Q1 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
4000000
CY2023Q1 zom Supplier Finance Program Obligation Noncurrent
SupplierFinanceProgramObligationNoncurrent
4000000
CY2023Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
3731000
CY2023Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
4933000
CY2023Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
4769000
CY2023Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
4536000
CY2023Q1 zom Finite Lived Intangible Assets Amortization Expense Year Four And Thereafter
FiniteLivedIntangibleAssetsAmortizationExpenseYearFourAndThereafter
30464000
CY2023Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
48433000
CY2023Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1199000
CY2022Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
737000
CY2023Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
199000
CY2022Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
152000
CY2023Q1 zom Operating Lease Right Of Use Asset Aggregate Lease Commitments
OperatingLeaseRightOfUseAssetAggregateLeaseCommitments
2759000
CY2022Q4 zom Operating Lease Right Of Use Asset Aggregate Lease Commitments
OperatingLeaseRightOfUseAssetAggregateLeaseCommitments
2759000
CY2023Q1 zom Operating Lease Right Of Use Asset Impact Of Present Value
OperatingLeaseRightOfUseAssetImpactOfPresentValue
262000
CY2022Q4 zom Operating Lease Right Of Use Asset Impact Of Present Value
OperatingLeaseRightOfUseAssetImpactOfPresentValue
262000
CY2023Q1 zom Operating Lease Right Of Use Asset Cost
OperatingLeaseRightOfUseAssetCost
2497000
CY2022Q4 zom Operating Lease Right Of Use Asset Cost
OperatingLeaseRightOfUseAssetCost
2497000
CY2023Q1 zom Operating Lease Right Of Use Asset Amortization
OperatingLeaseRightOfUseAssetAmortization
1119000
CY2022Q4 zom Operating Lease Right Of Use Asset Amortization
OperatingLeaseRightOfUseAssetAmortization
946000
CY2023Q1 zom Operating Lease Rightofuse Asset Interest
OperatingLeaseRightofuseAssetInterest
133000
CY2022Q4 zom Operating Lease Rightofuse Asset Interest
OperatingLeaseRightofuseAssetInterest
114000
CY2023Q1 zom Operating Lease Right Of Use Asset Accumulated Amortization
OperatingLeaseRightOfUseAssetAccumulatedAmortization
986000
CY2022Q4 zom Operating Lease Right Of Use Asset Accumulated Amortization
OperatingLeaseRightOfUseAssetAccumulatedAmortization
832000
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1511000
CY2023Q1 zom Operating Lease Liability Interest
OperatingLeaseLiabilityInterest
133000
CY2022 zom Operating Lease Liability Interest
OperatingLeaseLiabilityInterest
114000
CY2023Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
1582000
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
1738000
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
641000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
641000
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
941000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1097000
CY2023Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
1582000
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
1738000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
531000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
679000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
237000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
197000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
44000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1688000
CY2023Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
106000
CY2023Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
1582000
CY2023Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y8M12D
CY2023Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.045
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
6710000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
6710000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P4Y
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
14425000
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
14425000
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P4Y
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
84112443
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.3602
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
6710000
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.2431
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
705000
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0.4063
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
462500
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
1.5459
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
89654943
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.3449
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
27066474
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
0.3484
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
89654943
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
27066474
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
62588469
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.96
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0047
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P9Y6M10D
CY2020Q4 us-gaap Share Price
SharePrice
0.21
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
0.22
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.17
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0108
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y2M12D
CY2021Q4 us-gaap Share Price
SharePrice
0.65
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
0.65
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.12
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0309
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y11M1D
CY2022Q4 us-gaap Share Price
SharePrice
0.27
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
0.27
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.10
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0367
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y3M
CY2023Q1 us-gaap Share Price
SharePrice
0.24
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
0.24
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1765000
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2041000
CY2023Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
32561418
CY2023Q1 zom Sub Total Warrant Exercised Shares
SubTotalWarrantExercisedShares
360129250
CY2023Q1 zom Sub Total Warrant Amount
SubTotalWarrantAmount
56933000
CY2023Q1 zom Class Of Warrants Expired
ClassOfWarrantsExpired
351000
CY2023Q1 zom Warrants Expired Amount
WarrantsExpiredAmount
55000
CY2023Q1 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
2
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
5482000
CY2023Q1 us-gaap Cost Of Revenue
CostOfRevenue
1647000
CY2023Q1 us-gaap Gross Profit
GrossProfit
3835000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-6385000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-3937000
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-6385000
CY2022Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-3937000
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
979949668
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
979899668
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.007
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.004
CY2022Q1 us-gaap Related Party Transaction Amounts Of Transaction
RelatedPartyTransactionAmountsOfTransaction
10000

Files In Submission

Name View Source Status
zom-20230331_cal.xml Edgar Link unprocessable
0001558370-23-009389-index-headers.html Edgar Link pending
0001558370-23-009389-index.html Edgar Link pending
0001558370-23-009389.txt Edgar Link pending
0001558370-23-009389-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
zom-20230331.xsd Edgar Link pending
zom-20230331x10q.htm Edgar Link pending
zom-20230331xex31d1.htm Edgar Link pending
zom-20230331xex31d2.htm Edgar Link pending
zom-20230331xex32d1.htm Edgar Link pending
zom-20230331_def.xml Edgar Link unprocessable
zom-20230331_lab.xml Edgar Link unprocessable
zom-20230331_pre.xml Edgar Link unprocessable
zom-20230331x10q_htm.xml Edgar Link completed